Insulet Corporation

NASDAQ:PODD

Medical - Devices

Healthcare
$139.98 -2.82%

-$4.17 today

Market cap
$9.71B
Beta
1.13
P/E (TTM)
33.2
EPS (TTM)
$4.33
52W Low $140.63High $354.88

Volume 2.09M

Average 1.32M

PODD EBITDA Margin

EBITDA as a percentage of revenue.

Insulet CorporationNASDAQ: PODD

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 19.8%

EBITDA Margin was 19.8% in Q2 FY2026, up 9.0 pp from a year earlier. On a trailing-twelve-month basis it was 21.5%, up 4.3 pp year over year. Over 3 fiscal years it widened by 10.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 19 analysts of 24.0% for the fiscal year ending Dec 2026, up from 18.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
19.8%-0.4 pp QoQ
Last fiscal yearDec 2025
18.8%-1.6 pp YoY
LTMJun 2026
21.5%+4.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9.0 pp-1.2 pp-10.1 pp
1 year-1.6 pp+5.2 pp+6.8 pp
3 years+10.5 pp+6.5 pp-3.9 pp
5 years+10.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
18.8%
Year-over-year change
-1.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PODD compares with its peers on the latest reported figures

  • PODD's LTM Jun 2026 EBITDA Margin of 21.5% is the 2nd highest of the 5 companies compared; the peer median is -32.3%.
  • Its year-over-year change of +4.3 pp is the lowest of 5, against a peer median of +24.2 pp.
  • Over three fiscal years its change of +10.5 pp compares with a peer median of +0.9 pp.
PODD Competitors Peer median
EBITDA Margin for PODD and competitors
Company Period LTM level YoY 3-year change
DXCMDexCom, Inc.LTM Jun 202631.4% +7.2 pp+9.7 pp
PODDInsulet CorporationLTM Jun 202621.5% +4.3 pp+10.5 pp
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-7.0% +6.7 pp-8.0 pp
BBNXBeta Bionics, Inc.LTM Mar 2026-57.6% +41.1 pp+35348.3 pp
SENSSenseonics Holdings, Inc.LTM Mar 2026-198.5% +73.8 pp-1165.0 pp
Peer median (excluding PODD) -32.3%+24.2 pp+0.9 pp

Competitors are the stored peer set for PODD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.31B1.7B2.07B2.71B
Cost of Revenue346.7M499.7M537.2M625.9M768.2M
Gross Profit752.1M805.6M1.16B1.45B1.94B
Gross Margin68.4%61.7%68.3%69.8%71.6%
Research & Development160.1M180.2M205M219.6M301.1M
Selling, General & Admin466M587.8M734.9M917.2M1.17B
Operating Expenses626.1M768M939.9M1.14B1.47B
Depreciation & Amortization57.4M63.2M72.8M80.8M90.4M
EBITDA139.6M109M323.6M423.7M509.6M
EBITDA Margin12.7%8.4%19.1%20.5%18.8%
Operating Income126M37.6M220M308.9M473.8M
Operating Margin11.5%2.9%13.0%14.9%17.5%
Interest Income500K9.3M28.6M39.5M34.7M
Interest Expense61.7M36M36.2M42.7M79.7M
Other Income / Expenses(105.5M)(27.8M)(5.4M)(8.7M)(134.3M)
Income Before Tax20.5M9.8M214.6M300.2M339.5M
Pre-Tax Margin1.9%0.8%12.6%14.5%12.5%
Income Tax Expense3.7M5.2M8.3M(118.1M)92.4M
Net Income16.8M4.6M206.3M418.3M247.1M
Net Margin1.5%0.4%12.2%20.2%9.1%
EPS (Basic)0.250.072.965.973.51
EPS (Diluted)0.250.072.945.783.48
Weighted Avg Shares67.7M69.38M69.75M70.08M70.35M
Weighted Avg Shares (Diluted)68.58M69.91M73.63M73.89M71.89M

Insulet Corporation

NASDAQ:PODD

Intrinsic Alpha fair value

Locked

Current Price

$139.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.